# EDGAR Filing Document

**Accession Number:** 0001665988
**File Stem:** 0001665988-26-000012
**Filing Date:** 2026-3
**Character Count:** 15653
**Document Hash:** c1b1822d10783c64fcd7c823f6ca3421
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001665988-26-000012.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001665988-26-000012

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**EFFECTIVENESS DATE**: 20260305

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bioventus Inc.
- **CENTRAL INDEX KEY:** 0001665988
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 810980861
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294032
- **FILM NUMBER:** 26724216

**BUSINESS ADDRESS:**
- **STREET 1:** 4721 EMPEROR BOULEVARD, SUITE 100
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703
- **BUSINESS PHONE:** (919) 474-6700

**MAIL ADDRESS:**
- **STREET 1:** 4721 EMPEROR BOULEVARD, SUITE 100
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703

**As filed with the Securities and Exchange Commission on March 5, 2026**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**Bioventus Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **81-0980861** |
| **(State or other jurisdiction**<br>**of incorporation or organization)** | (I.R.S. Employer<br>Identification Number) |

---

**4721 Emperor Boulevard, Suite 100**

**Durham, North Carolina 27703**

**(Address of principal executive offices) (Zip code)**

**Bioventus Inc. 2021 Incentive Award Plan**

**Bioventus Inc. 2021 Employee Stock Purchase Plan**

**(Full title of the plans)**

**Robert E. Claypoole**

**President and Chief Executive Officer**

**Bioventus Inc.**

**4721 Emperor Boulevard, Suite 100**

**Durham, North Carolina 27703**

**(919) 474-6700**

**(Name and address of agent for service) (Telephone number, including area code, of agent for service)**

***With copies to:***

**Lorna A. Knick, Esq.**

**Nicholas C. Massey, Esq.**

**Wyrick Robbins Yates & Ponton LLP**

**4101 Lake Boone Trail, Suite 300**

**Raleigh, North Carolina 27607**

**Telephone: (919) 781-4000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☒ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☒

------

**EXPLANATORY NOTE**

Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 is being filed for the purpose of registering an additional 3,729,800 shares of Bioventus Inc.'s (the "Registrant") Class A common stock to be issued pursuant to the Bioventus Inc. 2021 Incentive Award Plan (the "2021 Plan") and an additional 670,977 shares of the Registrant's Class A common stock to be issued pursuant to the Bioventus Inc. 2021 Employee Stock Purchase Plan (the "2021 ESPP") and for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plans are effective.

**INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8** 

The contents of the Registration Statements on Form S-8 (<u>[File No. 333-252981](https://www.sec.gov/Archives/edgar/data/1665988/000119312521037596/d121205ds8.htm)</u>, <u>[File No. 333-263496](https://www.sec.gov/Archives/edgar/data/1665988/000162828022005925/bvsmarch2022s-8.htm)</u>, <u>[File No. 333-271310](https://www.sec.gov/Archives/edgar/data/1665988/000162828023011857/bvsapril2023s-8.htm)</u>, <u>[File No. 333-278100](https://www.sec.gov/Archives/edgar/data/1665988/000162828024012211/bvsmarch2024s-8.htm)</u>, and <u>[File No. 333-285698](https://www.sec.gov/Archives/edgar/data/1665988/000162828025011832/bvsmarch2025s-8.htm)</u>), filed with the Securities and Exchange Commission on February 11, 2021, March 11, 2022, April 18, 2023, March 20, 2024, and March 11, 2025, respectively, relating to the 2021 Plan and the 2021 ESPP, as amended, or as modified or superseded pursuant to Rule 412 under the Securities Act of 1933, as amended, are incorporated herein by reference.

**Part II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8. Exhibits**

---

| | |
|:---|:---|
| **Exhibit no.** | **Description** |
| 4.1 | <u>[Amended and Restated Certificate of Incorporation of Bioventus Inc. (incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K (File No. 001-37844) filed on February 17, 2021).](https://www.sec.gov/Archives/edgar/data/1665988/000119312521045802/d134776dex31.htm)</u> |
| 4.2 | <u>[Certificate of Amendment to Amended and Restated Certificate of Incorporation of Bioventus Inc. (incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K (File No. 001-37844) filed on June 17, 2024).](https://www.sec.gov/Archives/edgar/data/1665988/000119312524162669/d775079dex31.htm)</u> |
| 4.3 | <u>[Second Amended and Restated Bylaws of Bioventus Inc. (incorporated by reference to Exhibit 3.2 of the Registrant's Current Report on Form 8-K (File No. 001-37844) filed on June 17, 2024).](https://www.sec.gov/Archives/edgar/data/1665988/000119312524162669/d775079dex32.htm)</u> |
| 5.1\* | <u>[Opinion of Wyrick Robbins Yates & Ponton LLP](march2026s-8legalopinion.htm)</u>. |
| 23.1\* | <u>[Consent of Grant Thornton, Independent Registered Public Accounting Fir](march2026s-8consent.htm)</u><u>[m](march2026s-8consent.htm)</u>. |
| 23.2\* | <u>[Consent of Wyrick Robbins Yates & Ponton LLP (included in Exhibit 5.1](march2026s-8legalopinion.htm)</u><u>[)](march2026s-8legalopinion.htm)</u>. |
| 24.1\* | <u>[Power of Attorney (included on signature page)](#ib4d1a411dd994aabac1f603d3c5ce533_19)</u>. |
| 99.1 | <u>[Bioventus Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q (File No 001-37844), filed on August 12, 2022)](https://www.sec.gov/Archives/edgar/data/1665988/000162828022022592/exhibit103bioventusinc2021.htm)</u>. |
| 99.2 | <u>[Bioventus Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.44 to the Registrant's Registration Statement on Form S-1/A (File No. 333-252238), filed on February 4, 2021)](https://www.sec.gov/Archives/edgar/data/1665988/000119312521028021/d58473dex1044.htm)</u>. |
| 107.1\* | <u>[Filing Fee Table](exfilingfees.htm)</u>. |

---

\* Filed herewith

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on March 5, 2026.

---

| | | |
|:---|:---|:---|
| | **BIOVENTUS INC.** | **BIOVENTUS INC.** |
| Date: March 5, 2026 | By: | /s/ Robert E. Claypoole |
|  |  | Robert E. Claypoole<br>*President, Chief Executive Officer and Director (Principal Executive Officer)* |

---

------

**POWER OF ATTORNEY**

Each person whose signature appears below hereby constitutes and appoints Robert E. Claypoole and Mark L. Singleton, or each of them singly, with full power to act without the other, such person's true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

------

---

| | | |
|:---|:---|:---|
| **Name** | **Date** | **Title** |
| /s/ Robert E. Claypoole | March 5, 2026 | President, Chief Executive Officer and Director <br>(Principal Executive Officer) |
| Robert E. Claypoole |  | President, Chief Executive Officer and Director <br>(Principal Executive Officer) |
| /s/ Mark L. Singleton | March 5, 2026 | Senior Vice President and Chief Financial Officer <br>(Principal Financial Officer and Principal Accounting Officer) |
| Mark L. Singleton |  | Senior Vice President and Chief Financial Officer <br>(Principal Financial Officer and Principal Accounting Officer) |
| /s/ William A. Hawkins III | March 5, 2026 | Chairman |
| William A. Hawkins III |  |  |
| /s/ John A. Bartholdson | March 5, 2026 | Director |
| John A. Bartholdson |  |  |
| /s/ Patrick J. Beyer | March 5, 2026 | Director |
| Patrick J. Beyer |  |  |
| /s/ Philip G. Cowdy | March 5, 2026 | Director |
| Philip G. Cowdy |  |  |
| /s/ Ajay Dhankhar | March 5, 2026 | Director |
| Ajay Dhankhar |  |  |
| /s/ Mary Kay Ladone | March 5, 2026 | Director |
| Mary Kay Ladone |  |  |
| /s/ Michelle McMurry-Heath | March 5, 2026 | Director |
| Michelle McMurry-Heath |  |  |
| /s/ Guido J. Neels | March 5, 2026 | Director |
| Guido J. Neels |  |  |
| /s/ Guy P. Nohra | March 5, 2026 | Director |
| Guy P. Nohra |  |  |
| /s/ Susan M. Stalnecker | March 5, 2026 | Director |
| Susan M. Stalnecker |  |  |
| /s/ Martin P. Sutter | March 5, 2026 | Director |
| Martin P. Sutter |  |  |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**Exhibit 107.1**

**Calculation of Filing Fee Tables**

**Form S-8**

(Form Type)

**Bioventus Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Table 1—Newly Registered Securities**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount<br>to be<br>Registered (1)** | **Proposed<br>Maximum<br>Offering Price<br>Per Unit** | **Maximum<br>Aggregate<br>Offering Price** | **Fee Rate** | **Amount of<br>Registration Fee** |
| Equity | Class A common stock, $0.001 par value per share | Rule 457(c) and Rule 457(h)(1) | 4400777 (2) | $8.54 (3)  | $37582635.58 | $138.10 per 1,000,000 | $5190.16 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $37582635.58 |  | $5190.16 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | $— |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $5190.16 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Consists of an additional 3,729,800 shares of Bioventus Inc.'s (the "Registrant") Class A common stock issuable pursuant to the Bioventus Inc. 2021 Incentive Award Plan and an additional 670,977 shares of the Registrant's Class A common stock issuable pursuant to the Bioventus Inc. 2021 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h)(1) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrant's Class A common stock as reported on The Nasdaq Global Select Market on March 2, 2026.

## Exhibit 5.1

**Exhibit 5.1**

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607-7506

March 5, 2026

Bioventus Inc.

4721 Emperor Boulevard, Suite 100

Durham, North Carolina 27703

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 filed on or about the date hereof by Bioventus Inc., a Delaware corporation (the "Registrant"), with the U.S. Securities and Exchange Commission (the "Registration Statement"), in connection with the registration under the Securities Act of 1933, as amended, of an aggregate of 4,400,777 shares of the Registrant's Class A common stock, $0.001 par value per share (the "Shares"). We understand that 3,729,800 Shares are to be issued pursuant to the Bioventus Inc. 2021 Incentive Award Plan and 670,977 Shares are to be issued pursuant to the Bioventus Inc. 2021 Employee Stock Purchase Plan (each referred to individually as the "Plan" and collectively as the "Plans"). In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity with the original of all documents submitted to us as copies thereof.

As the Registrant's legal counsel, we have examined the proceedings taken, and are familiar with the proceedings proposed to be taken, in connection with the sale of the Shares pursuant to the Plans.

It is our opinion that, upon completion of the proceedings being taken or contemplated by us, as the Registrant's counsel, to be taken prior to the issuance of the Shares, the Shares when issued in the manner referred to in the Registration Statement and in accordance with the applicable Plan, will be validly issued, fully paid and nonassessable.

We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to the use of our name wherever appearing in the Registration Statement, including the prospectus constituting a part thereof, and any amendments thereto.

---

| |
|:---|
| Sincerely, |
| /s/ WYRICK ROBBINS YATES & PONTON LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We have issued our report dated March 5, 2026 with respect to the consolidated financial statements of Bioventus Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2025, which is incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the aforementioned report in this Registration Statement.

/s/ GRANT THORNTON LLP

Raleigh, North Carolina

March 5, 2026

<br>